MetTrimMD Dallas operates as a medical weight loss clinic in Dallas, Texas, under the supervision of Dr. Michael Tran. The practice concentrates on pharmacological interventions for metabolic dysfunction and obesity management, utilizing FDA-approved GLP-1 receptor agonists and adjunctive peptide therapies. Patients receive structured protocols that combine medication management with metabolic monitoring to address weight plateau, insulin resistance, and body composition challenges specific to the Dallas metropolitan area.
The clinic's treatment framework centers on semaglutide and tirzepatide as primary weight loss agents, both administered via subcutaneous injection on weekly schedules. Semaglutide dosing typically begins at 0.25 mg weekly and titrates upward based on tolerance and response, while tirzepatide follows a similar escalation pattern starting at 2.5 mg. Beyond GLP-1 therapy, MetTrimMD Dallas incorporates peptide protocols including CJC-1295, a growth hormone-releasing hormone analog used to support lean muscle preservation during caloric restriction, and BPC-157, a gastric peptide sequence applied for gut health optimization and tissue repair. These peptides are prescribed as adjuncts when patients demonstrate specific metabolic needs or recovery requirements during their weight loss phase.
Dr. Michael Tran directs clinical operations and patient care at the Dallas location, conducting initial consultations that include comprehensive metabolic panel analysis, thyroid function assessment, and body composition measurement via bioelectrical impedance or DEXA scanning when indicated. His approach emphasizes identifying underlying metabolic barriers—such as hypothyroidism, cortisol dysregulation, or sex hormone imbalances—that may impede weight loss progress. Treatment plans are individualized based on laboratory findings, medical history, and patient-specific goals, with medication selection and dosing adjusted according to response patterns and side effect profiles observed during bi-weekly monitoring visits.
Patients at MetTrimMD Dallas follow a structured monitoring schedule with check-ins every two weeks during the active weight loss phase. These appointments include weight and vital sign measurement, medication tolerance assessment, and protocol adjustments as needed. The bi-weekly cadence allows for timely intervention if patients experience gastrointestinal side effects common to GLP-1 therapies—such as nausea or constipation—or if weight loss velocity deviates from expected trajectories. Metabolic testing is repeated at regular intervals to track improvements in fasting glucose, hemoglobin A1c, lipid panels, and inflammatory markers, providing objective data to guide treatment decisions and demonstrate physiological changes beyond scale weight.
The clinic serves patients throughout Dallas and surrounding communities in North Texas, offering in-person visits at their Dallas facility. MetTrimMD Dallas maintains a focus on medically supervised programs rather than over-the-counter supplements or unmonitored peptide use, requiring physician oversight for all prescription therapies. This medical framework distinguishes the practice from wellness spas or non-physician-led weight loss centers, ensuring that patients with comorbid conditions such as type 2 diabetes, hypertension, or cardiovascular disease receive appropriate screening and monitoring throughout their treatment course.
MyPeptideMatch.com is an independent directory. We do not provide medical advice. Always consult a qualified healthcare provider before starting any peptide therapy.
